Advancements in the management of uveitis |
| |
| Affiliation: | 1. Assistance Publique-Hôpitaux de Paris (AP-HP), Groupement Hospitalier Pitié-Salpêtrière (GHPS), French National Reference Center for Rare Systemic Auto-immune Diseases, Service de Médecine interne 2, Paris, France;2. Inserm, U1135, Centre d''Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France;3. Université Pierre et Marie Curie, Univ Paris 06, Paris, France;4. AP-HP, GHPS, Département d''Immunologie, Paris, France;5. AP-HP, GHPS, Service de Radiologie, Paris, France;1. Ocular Imaging Research and Reading Center (OIRRC), Omaha, NE, USA;2. Rush University Medical Center, Chicago, IL, USA;3. Duke University, Durham, NC, USA;4. University of Bristol, Bristol Eye Hospital, Bristol, UK;5. National Institute for Health Research (NIHR) Biomedical Research Centre, London, UK;6. Moorfields Eye Hospital and University College London, Institute of Ophthalmology, London, UK;7. Wake Forest Baptist Medical Center, Winston-Salem, NC, USA;8. Lions Medical Eye Bank of Eastern Virginia, Eastern Virginia Medical School and Virginia Eye Consultants, Norfolk, VA, USA;9. Austral University, Buenos Aires, Argentina;10. Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia RE, Italy;11. University Hospitals Leuven, Leuven, Belgium;12. AbbVie Deutschland, Ludwigshafen, Germany;13. AbbVie, North Chicago, IL, USA;14. Université Paris Descartes, Hôpital Cochin, Paris, France;1. Aravind Eye Care System, Madurai, India;2. Aravind Eye Care System, Coimbatore, India;3. F.I. Proctor Foundation, University of California, San Francisco, California;4. Department of Epidemiology & Biostatistics, University of California, San Francisco, California;5. Department of Ophthalmology, University of California, San Francisco, California |
| |
| Abstract: | Uveitis may exist as a clinical manifestation of an underlying systemic disease or may represent an idiopathic entity, sometimes with a very characteristic pattern. Different forms of uveitis have been defined on the basis of three important variables: chronicity, anatomic location, and underlying etiology. The evolving understanding of the immune system has resulted in a more targeted approach to manage patients with different forms of uveitis, although clearly this approach is at a very early stage.Altered patterns of cellular processing and different cytokine expression, including TNF, IL-1, IL-2, IL-6, and IL17, have been defined in uveitis, and this has laid the pathway for targeted therapy. Furthermore, approved biologic therapies for some of the more common autoimmune illnesses have now been tested in uveitis. Adalimumab and infliximab have been the best studied anti-TNF agents and indeed have now been recommended by an expert panel as the first line of treatment for ocular manifestations of Behçet's disease and the second line of treatment for other forms of uveitis. Adalimumab has been recently approved for intermediate uveitis, posterior uveitis, and panuveitis. Other biologic agents have been tested, including daclizumab, a monoclonal antibody directed against IL-2, anti-IL1, and anti-IL-6 receptor agents and therapies that block antigen-presenting cell and T-cell interaction, such as abatacept. In small case series, other biologics such as interferon and rituximab have also been evaluated.Although these biologic therapies have provided a larger armamentarium to treat uveitis, challenges remain. Uveitis is not a disease, but a manifestation of many potential systemic diseases that may have specific individual therapeutic targets. Identification and characterization of these underlying diseases are not always possible and, more importantly, the most effective therapies for each entity have not been defined. In this study, an approach to manage patients with uveitis is presented and current therapy is reviewed. |
| |
| Keywords: | Autoimmune ophthalmic disease Uveitis Biologic therapy Ocular complications |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
